Dr. Muggia on Targeted Therapies for Ovarian Cancer

Franco M. Muggia, MD, PhD
Published: Wednesday, May 03, 2017



Franco M. Muggia, MD, PhD, professor, Department of Medicine, NYU Langone Medical Center, discusses targeted therapies for patients with ovarian cancer.

The BRCA mutations occur in many of the patients with high-grade serous ovarian cancers, explains Muggia. For patients with low-grade serous disease, the major target is estrogen receptors—making anti-estrogen agents beneficial.

Though the drugs have been effective, researchers need to continue to increase the number of cures that are seen with this disease, states Muggia.
 


Franco M. Muggia, MD, PhD, professor, Department of Medicine, NYU Langone Medical Center, discusses targeted therapies for patients with ovarian cancer.

The BRCA mutations occur in many of the patients with high-grade serous ovarian cancers, explains Muggia. For patients with low-grade serous disease, the major target is estrogen receptors—making anti-estrogen agents beneficial.

Though the drugs have been effective, researchers need to continue to increase the number of cures that are seen with this disease, states Muggia.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x